Scholar Rock Holding Corporation (SRRK) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-03-03
Business type: Asset play
How it makes money
It expects to generate revenue by selling apitegromab to treat an estimated 35,000 global spinal muscular atrophy patients receiving SMN-targeted therapies.
The company produces no revenue currently, but is transitioning to a commercial-stage model focused on apitegromab. This monoclonal antibody is designed to improve motor function in patients already receiving standard-of-care treatments like nusinersen or risdiplam.
Profitability depends on the drug's success as a muscle-targeted therapy that complements existing SMN-directed treatments. The primary target is the prevalent population of non-ambulatory Type 2 and Type 3 patients who still suffer functional deficits despite current standard care.
What protects it: the moat
It maintains exclusivity through a proprietary platform that targets the structurally diverse latent prodomain cages of growth factors instead of mature forms.
Management claims its technology enables unprecedented selectivity by inhibiting growth factors before they are activated in the tissue microenvironment. While mature myostatin is 90% identical to GDF11, the prodomain cage that surrounds it is only 52% identical, allowing the company to avoid off-target side effects.
This structural focus aims to overcome the vascular toxicity and hormonal suppression that previously caused the termination of competing myostatin-inhibition programs at rival firms. Its lead candidate is the only myostatin inhibitor to achieve a statistically significant Phase 3 outcome.
What growth costs
Reinvestment focused on commercial infrastructure and R&D, resulting in a $377.9 million net loss and an accumulated deficit of $1.3 billion.
The company is spending heavily to build a 50-person U.S. commercial organization and establish a European presence starting in Germany for the planned 2026 launch.
Ongoing clinical costs are driven by the Phase 2 OPAL study for infants, the Phase 2 FORGE trial for facioscapulohumeral muscular dystrophy, and the development of SRK-439. These programs require continuous capital for manufacturing process development and clinical drug supply.
What could damage it
Operational reliance on single-source partners led to a Complete Response Letter after an FDA inspection of a third-party fill-finish facility.
In September 2025, the FDA delayed the commercialization of apitegromab due to manufacturing deficiencies at an external site. Although the agency cited no concerns regarding efficacy or safety data, the facility was classified as OAI, creating a regulatory bottleneck.
This delay allows competitors to potentially gain ground and forces the company to maintain a high burn rate without revenue until the third party resolves its compliance issues and the license application is resubmitted.
About Scholar Rock Holding Corporation
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.